Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merck & Co and Danish pharmaceutical Lundbeck have delayed filing their joint new drug application for gaboxadol with the FDA.
Subscribe to our email newsletter
The application was supposed to be filed in the first quarter of 2007. The companies now plan to submit the new drug application in mid-2007.
The companies said the delay in the submission for gaboxadol resulted from slower than anticipated enrollment in ongoing phase III trials.
Gaboxadol is a novel investigational drug in phase III development for the treatment of insomnia. In 2004, the companies agreed to collaborate on the development and commercialization of gaboxadol in the US.